HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

S100 Genes are Highly Expressed in Peripheral Leukocytes of Type 2 Diabetes Mellitus Patients Treated with Dietary Therapy.

AbstractBACKGROUND AND OBJECTIVES:
We demonstrated that the mRNA induction of S100s in rat peripheral leukocytes by severe hyperglycemia was reduced by inhibiting postprandial hyperglycemia. Here, we compared inflammatory gene expression in peripheral leukocytes between type 2 diabetes mellitus (T2DM) patients undergoing dietary therapy alone and healthy volunteers, and between T2DM patients undergoing dietary therapy alone and those undergoing such therapy in combination with drug therapy using the α-glucosidase inhibitor miglitol.
METHODS:
T2DM patients who had undertaken dietary therapy alone or in combination with drug therapy using miglitol for ≥ 8 weeks and healthy volunteers were subjected to a meal tolerance test and glucose concentration, neutrophil elastase concentration, and mRNA expression analyses of peripheral leukocytes by microarray and quantitative reverse-transcription polymerase chain reaction (qRT-PCR) immediately before and 180 min after a meal.
RESULTS:
Blood glucose concentrations 60 min after a meal were lower in T2DM patients with dietary + miglitol therapy than in those with dietary therapy alone. Neutrophil elastase concentrations at 60 and 120 min after a meal were lower in T2DM patients with dietary + miglitol therapy than in those with dietary therapy alone. Expression levels of S100A8 in a fasting state and S100A6, S100A8, and S100A9 180 min after a meal were higher in T2DM patients with dietary therapy alone than in healthy volunteers. Expression levels of S100A12 in a fasting state and 180 min after a meal were higher in T2DM patients with dietary therapy alone than in T2DM patients with dietary + miglitol therapy.
CONCLUSIONS:
S100 genes were more highly expressed in T2DM patients with dietary therapy than in healthy volunteers.
AuthorsShinnosuke Kondo, Kazuki Mochizuki, Natsuyo Hariya, Miyoko Saito, Satako Doguchi, Takeshi Osonoi
JournalDrugs in R&D (Drugs R D) Vol. 21 Issue 1 Pg. 91-101 (Mar 2021) ISSN: 1179-6901 [Electronic] New Zealand
PMID33464544 (Publication Type: Clinical Trial, Journal Article)
Chemical References
  • Cytokines
  • Hypoglycemic Agents
  • RNA, Messenger
  • S100 Proteins
  • miglitol
  • 1-Deoxynojirimycin
Topics
  • 1-Deoxynojirimycin (analogs & derivatives, therapeutic use)
  • Adult
  • Aged
  • Cytokines (genetics, metabolism)
  • Diabetes Mellitus, Type 2 (blood, diet therapy, drug therapy)
  • Fasting (blood)
  • Female
  • Gene Expression Regulation
  • Hospitals, University
  • Humans
  • Hypoglycemic Agents (therapeutic use)
  • Inflammation (genetics, metabolism)
  • Leukocytes (metabolism)
  • Male
  • Middle Aged
  • Prospective Studies
  • RNA, Messenger (analysis)
  • S100 Proteins (genetics, metabolism)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: